Literature DB >> 6108568

Purinergic nerves and receptors.

G Burnstock.   

Abstract

The presence of a non-cholinergic, non-adrenergic component in the vertebrate autonomic nervous system is now well established. Evidence that ATP is the transmitter released from some of these nerves (called "purinergic') includes: (a) synthesis and storage of ATP in nerves: (b) release of ATP from the nerves when they are stimulated; (c) exogenously applied ATP mimicking the action of nerve-released transmitter; (d) the presence of ectoenzymes which inactivate ATP; (e) drugs which produce similar blocking or potentiating effects on the response to exogenously applied ATP and nerve stimulation. A basis for distinguishing two types of purinergic receptors has been proposed according to four criteria: relative potencies of agonists, competitive antagonists, changes in levels of cAMP and induction of prostaglandin synthesis. Thus P1 purinoceptors are most sensitive to adenosine, are competitively blocked by methylxanthines and their occupation leads to changes in cAMP accumulation; while P2 purinoceptors are most sensitive to ATP, are blocked (although not competitively) by quinidine, 2-substituted imidazolines, 2,2'-pyridylisatogen and apamin, and their occupation leads to production of prostaglandin. P2 purinoceptors mediate responses of smooth muscle to ATP released from purinergic nerves, while P1 purinoceptors mediate the presynaptic actions of adenosine on adrenergic, cholinergic and purinergic nerve terminals.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6108568

Source DB:  PubMed          Journal:  Prog Biochem Pharmacol        ISSN: 0079-6085


  15 in total

1.  Studies on the receptor mediating cyclic AMP-independent enhancement by adenosine of IgE-dependent mediator release from rat mast cells.

Authors:  M K Church; P J Hughes; C J Vardey
Journal:  Br J Pharmacol       Date:  1986-01       Impact factor: 8.739

2.  Adenosine inhibits and potentiates IgE-dependent histamine release from human basophils by an A2-receptor mediated mechanism.

Authors:  M K Church; S T Holgate; P J Hughes
Journal:  Br J Pharmacol       Date:  1983-12       Impact factor: 8.739

Review 3.  Nomenclature and classification of purinoceptors.

Authors:  B B Fredholm; M P Abbracchio; G Burnstock; J W Daly; T K Harden; K A Jacobson; P Leff; M Williams
Journal:  Pharmacol Rev       Date:  1994-06       Impact factor: 25.468

4.  The agonists for nociceptors are ubiquitous, but the modulators are specific: P2X receptors in the sensory neurons are modulated by cannabinoids.

Authors:  O Krishtal; N Lozovaya; A Fedorenko; I Savelyev; I Chizhmakov
Journal:  Pflugers Arch       Date:  2006-06-02       Impact factor: 3.657

Review 5.  TNF-alpha and neuropathic pain--a review.

Authors:  Lawrence Leung; Catherine M Cahill
Journal:  J Neuroinflammation       Date:  2010-04-16       Impact factor: 8.322

6.  P2-purinoceptors regulate surfactant secretion from rat isolated alveolar type II cells.

Authors:  W R Rice; F M Singleton
Journal:  Br J Pharmacol       Date:  1986-11       Impact factor: 8.739

7.  Relative contribution of ecto-ATPase and ecto-ATPDase pathways to the biphasic effect of ATP on acetylcholine release from myenteric motoneurons.

Authors:  M Duarte-Araújo; C Nascimento; M A Timóteo; M T Magalhães-Cardoso; P Correia-de-Sá
Journal:  Br J Pharmacol       Date:  2009-01-13       Impact factor: 8.739

8.  Pharmacological dissection of the cellular mechanisms associated to the spontaneous and the mechanically stimulated ATP release by mesentery endothelial cells: roles of thrombin and TRPV.

Authors:  M Verónica Donoso; Felipe Hernández; Tania Villalón; Claudio Acuña-Castillo; J Pablo Huidobro-Toro
Journal:  Purinergic Signal       Date:  2018-01-19       Impact factor: 3.765

9.  Communication between corneal epithelial cells and trigeminal neurons is facilitated by purinergic (P2) and glutamatergic receptors.

Authors:  Duane J Oswald; Albert Lee; Monique Trinidad; Cheryl Chi; Ruiyi Ren; Celeste B Rich; Vickery Trinkaus-Randall
Journal:  PLoS One       Date:  2012-09-07       Impact factor: 3.240

Review 10.  Purinergic Signaling in the Pathophysiology and Treatment of Huntington's Disease.

Authors:  Melissa Talita Wiprich; Carla Denise Bonan
Journal:  Front Neurosci       Date:  2021-07-01       Impact factor: 4.677

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.